Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 4215 (115th)

To amend title XVIII of the Social Security Act to ensure that providers of services receive adequate payments for the acquisition of hematopoietic stem cells under the Medicare program, and for other purposes.

referredUnited States· United States Congress· EN

Introduced

1 November 2017

Last action

1 November 2017 · Introduced

Status

Referred to the House Committee on Ways and Means.

Sponsors

Rep. Paulsen, Erik [R-MN-3], Rep. Kind, Ron [D-WI-3], Rep. Matsui, Doris O. [D-CA-7], Rep. Bilirakis, Gus M. [R-FL-12], Rep. Blumenauer, Earl [D-OR-3], Rep. McCollum, Betty [D-MN-4], Rep. Peterson, Collin C. [D-MN-7], Rep. Jenkins, Lynn [R-KS-2], Sen. Marshall, Roger [R-KS], Rep. Lofgren, Zoe [D-CA-18], Rep. Smith, Christopher H. [R-NJ-4], Rep. Beatty, Joyce [D-OH-3], Rep. Lewis, John [D-GA-5], Rep. Hudson, Richard [R-NC-8], Rep. Ross, Dennis A. [R-FL-15], Rep. Rooney, Thomas J. [R-FL-17], Rep. Carbajal, Salud O. [D-CA-24], Rep. Meehan, Patrick [R-PA-7], Rep. Shea-Porter, Carol [D-NH-1], Rep. Khanna, Ro [D-CA-17], Rep. Emmer, Tom [R-MN-6], Rep. Thompson, Mike [D-CA-4], Rep. Crist, Charlie [D-FL-13], Rep. DeFazio, Peter A. [D-OR-4], Rep. Marchant, Kenny [R-TX-24], Rep. Roskam, Peter J. [R-IL-6], Rep. Esty, Elizabeth H. [D-CT-5]

Subjects

Healthcare

Source updated

3 January 2025

Healthcare

Summary

This bill requires the Centers for Medicare & Medicaid Services to pay, to a provider that furnishes a hematopoietic stem cell transplant, an adjusted Medicare payment consistent with the Medicare payment methodology for kidney-acquisition costs outlined in regulation. Under the applicable regulation, kidney-acquisition costs are treated apart from the prospective payment rate for inpatient operating costs, and payment is adjusted to compensate the hospital for certain reasonable expenses. "Hematopoietic stem cell transplant" means the infusion of allogeneic hematopoietic cells (including bone marrow, peripheral blood stem cells, and cord-blood units, but excluding embryonic stem cells) that are: (1) not more than minimally manipulated; and (2) intended to reestablish hematopoietic function in an individual whose blood marrow or immune system is damaged, defective, or adversely affective by a congenital disorder.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 1 November 2017

    Introduced

    Referred to the House Committee on Ways and Means.

    Source: IntroReferral

  2. 1 November 2017

    Introduced

    Introduced in House

    Source: IntroReferral

  3. 1 November 2017

    Introduced

    Introduced in House

    Source: IntroReferral

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 1 November 2017

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 1 November 2017

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 1 November 2017

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.